Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04529174 · ClinicalTrials.gov registry record · NA
Oral Nutritional Supplement Effect on HDL Function
A NA study, sponsored by Metagenics.
- Completed
- Registry status
- NA
- Development phase
- 53
- Enrollment target
NCT04529174: Completed NA study, sponsored by Metagenics.
NCT04529174 is a NA study that has completed, run by Metagenics. The registered enrollment target is 53 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04529174, a NA study, has completed, sponsored by Metagenics.
- COMPLETED
- Registry status
- NA
- Development phase
- 53 participants
- Enrollment target
Study Summary
Evaluate the effects of a proprietary supplement on total HDL, HDL functionality, HDL particle size and HDL particle number (HDL-P)
Primary Outcome
Reverse Cholesterol Transport (RCT)(CEC) with Cleveland Heart Lab (CHL)
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT CardioLux™HDL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2020-08-18 |
| Est. Completion | 2023-12-30 |
| Phase | NA |
What the finished NCT04529174 record still lists
NCT04529174 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 53 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04529174 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04529174 about?
NCT04529174 is a clinical study titled "Oral Nutritional Supplement Effect on HDL Function". Evaluate the effects of a proprietary supplement on total HDL, HDL functionality, HDL particle size and HDL particle number (HDL-P)
What is the current status of trial NCT04529174?
This trial is currently completed. It is a NA study. The enrollment target is 53 participants. The study started on 2020-08-18. Estimated completion is 2023-12-30.
What interventions are being tested in trial NCT04529174?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), CardioLux™HDL (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT04529174?
This trial is sponsored by Metagenics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04529174's enrollment target sits among peer trials
53 1271st of 2000 higher than 729 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04177004 · 53 participants · Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- NCT04199741 · 53 participants · Phase 1
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
- NCT04835129 · 53 participants · Phase 2
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
- NCT04913805 · 53 participants · Phase 2
Matching Perfusion and Metabolic Activity in HFpEF
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI